Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous Human Enterovirus 71 strains in mice

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Meng, Tao ^a   Kolpe, Annasaheb B ^a   Kiener, Tanja K ^a   Chow, Vincent T K ^b   Kwang, Jimmy ^a,b  

^a Animal Health Biotechnology   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA DIRECTED RNA POLYMERASE; HYBRID PROTEIN; PROTEIN VP1 GP64 FUSION PROTEIN; UNCLASSIFIED DRUG; CAPSID PROTEIN; RECOMBINANT DNA; VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACULOVIRUS; CELL MEMBRANE; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; GENETIC ANALYSIS; IMMEDIATE EARLY GENE; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IMMUNOPHARMACOLOGY; IN VITRO STUDY; INSECT CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVERSE GENETICS; TRANSMISSION ELECTRON MICROSCOPY; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS RELEASE; VIRUS STRAIN; WESTERN BLOTTING; WHITE SPOT SYNDROME VIRUS; ANIMAL; ANTIBODY SPECIFICITY; ARMYWORM; BAGG ALBINO MOUSE; BLOOD; CELL LINE; CYTOLOGY; ENTEROVIRUS; GENETIC ENGINEERING; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; METABOLISM; PATHOGENICITY; SERODIAGNOSIS;

HEXAPODA; HUMAN ENTEROVIRUS 71; MIRIDAE; MUS; SHRIMP WHITE SPOT SYNDROME VIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; BACULOVIRIDAE; CAPSID PROTEINS; CELL LINE; DNA, COMPLEMENTARY; DNA, RECOMBINANT; ENTEROVIRUS A, HUMAN; FEMALE; GENETIC ENGINEERING; HUMANS; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RNA POLYMERASE I; SPODOPTERA; VACCINES;

EID: 79959781882     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021757     Document Type: Article

References (54)

1. AbuBakar S, Sam IC, Yusof J, Lim MK, Misbah S, et al. (2009) Enterovirus 71 outbreak, Brunei. Emerg Infect Dis 15 (1): 79-82.
2. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, et al. (2000) Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 31 (3): 678-683.
3. Chang LY, (2008) Enterovirus 71 in Taiwan. Pediatr Neonatol 49 (4): 103-112.
4. Liu CC, Tseng HW, Wang SM, Wang JR, Su IJ, (2000) An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol 17 (1): 23-30.
5. Singh S, Chow VTK, Phoon MC, Chan KP, Poh CL, (2002) Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers. J Clin Microbiol 40 (8): 2823-2827.
6. Van der Sanden S, Koopmans M, Uslu G, van der Avoort H, (2009) Epidemiology of enterovirus 71 in the Netherlands, 1963-2008. J Clin Microbiol 47 (9): 2826-2833.
7. Ho M, (2000) Enterovirus 71: the virus, its infections, and outbreaks. J Microbiol Immunol Infect 33 (4): 205-216.
8. Bible JM, Pantelidis P, Chan PK, Tong CY, (2007) Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol 17 (6): 371-379.
9. McMinn PC, (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26 (1): 91-107.
10. Qiu J, (2008) Enterovirus 71 infection: a new threat to global public health? Lancet Neurol 7 (10): 868-869.
11. Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, et al. (2010) The largest outbreak of hand, foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Inf Dis 14: e1076-e1081.
12. Ranganathan S, Singh S, Poh CL, Chow VT, (2002) The hand, foot and mouth disease virus capsid: sequence analysis and prediction of antigenic sites from homology modelling. Appl Bioinformatics 1 (1): 43-52.
13. Takeda N, Tanimura M, Miyamura K, (1994) Molecular evolution of the major capsid protein VP1 of enterovirus 71. J Virol 68 (2): 854-862.
14. Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, et al. (2010) Evolutionary Genetics of Human Enterovirus 71: Origin, Population Dynamics, Natural Selection, and Seasonal Periodicity of the VP1 Gene. J Virol 84 (7): 3339-3350.
15. Tan CS, Cardosa MJ, (2007) High-titred neutralizing antibodies to human enterovirus preferentially bind to the N-terminal portion of the capsid protein VP1. Arch. Virol 152 (6): 1069-1073.
16. Sivasamugham LA, Cardosa MJ, Tan WS, Yusoff K, (2006) Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J Med Virol 78 (8): 1096-1104.
17. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20 (5-6): 895-904.
18. Liu JN, Wang W, Duo JY, Hao Y, Ma CM, et al. (2010) Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28 (46): 7444-51.
19. Chiu CH, Chu C, He CC, Lin TY, (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8 (7): 1671-1678.
20. Foo DG, Alonso S, Chow VT, Poh CL, (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9 (11): 1299-1306.
21. Li X, Mao C, Ma S, Wang X, Sun Z, et al. (2009) Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 390 (4): 1126-1128.
22. Tung WS, Bakar SA, Sekawi Z, Rosli R, (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.
23. Miller, K L, (1988) Baculoviruses for foreign gene expression in insect cells. Biotechnology 10: 457-465.
24. Whitford, Stewart S M, Kuzio J, Faulkner P, (1989) Identification and sequence analysis of a gene encoding gp67, an abundant envelope glycoprotein of the baculovirus Autographa californica nuclear polyhedrosis. J Virol 63 (3): 1393-1399.
25. Monsma SA, Oomens GP, Blissard GW, (1996) The GP64 envelope fusion protein is an essential baculovirus protein required for cell-to-cell transmission of infection. J Virol 70 (7): 4607-4616.
26. Kitagawa Y, Tani H, Limn CK, Matsunaga TM, Moriishi K, et al. (2005) Ligand directed gene targeting to mammalian cells by pseudotype baculoviruses. J Virol 79 (6): 3639-3652.
27. Tami C, Peralta A, Barbieri R, Berinstein A, Carrillo E, et al. (2004) Immunological properties of FMDV-gP64 fusion proteins expressed on SF9 cell and baculovirus surfaces. Vaccine 23 (6): 840-845.
28. Lin YH, Lee LH, Shih WL, Hu YC, Liu HJ, (2008) Baculovirus surface display of σC and σB proteins of avian reovirus and immunogenicity of the displayed proteins in a mouse model. Vaccine 26 (50): 6361-6367.
29. Syed Musthaq S, Madhan S, Sahul Hameed AS, Kwang J, (2009) Localization of VP28 on the baculovirus envelope and its immunogenicity against white spot syndrome virus in Penaeus monodon. Virology 391 (2): 315-324.
30. Gao H, Wang Y, Li N, Peng WP, Sun Y, et al. (2007) Efficient gene delivery into mammalian cells mediated by a recombinant baculovirus containing a whispovirus ie1 promoter, a novel shuttle promoter between insect cells and mammalian cells. J Biotechnol 131 (2) 138-143.
31. Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J, (2010) Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol 84 (7): 3201-3209.
32. Yang F, Ren LL, Xiong ZH, Li JG, Xiao Y, et al. (2009) Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 47 (7): 2351-2352.
33. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG, (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97 (11): 6108-6113.
34. Ho HT, Qian HL, He F, Meng T, Szyporta M, et al. (2009) Rapid Detection of H5N1 Subtype Influenza Viruses by Antigen Capture Enzyme-Linked Immunosorbent Assay Using H5- and N1-Specific Monoclonal Antibodies Clin Vaccine Immunol 16 (5): 726-732.
35. Chang Y, Zheng H, Shang Y, Jin Y, Wang G, et al. (2009) Recovery of infectious foot-and-mouth disease virus from full-length genomic cDNA clones using an RNA polymerase I system. Acta Biochim Biophys Sin 41 (12): 998-1007.
36. Cello J, Paul AV, Wimmer E, (2002) Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 297 (5583): 1016-1018.
37. LaBarre DD, Lowy RJ, (2001) Improvements in methods for calculating virus titer estimating TCID50 and plaque assays. J. Virol. Methods 96 (2): 107-126.
38. O'Reilly DM, Luckow V, (1992) Baculovirus Expression Vectors. A Laboratory Manual New York W.H. Freeman and Co.
39. Arita M, Shimizu H, Nagata N, Ami Y, Suzaki Y, et al. (2005) Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J Gen Virol 86 (pt 5): 1391-1401.
40. Grabherr R, Ernst W, (2010) Baculovirus for Eukaryotic Protein Display. Curr Gene Ther 10 (3): 195-200.
41. He F, Madhan S, Kwang J, (2009) Baculovirus vector as a delivery vehicle for influenza vaccines. Expert Rev. Vaccines 8 (4): 455-467.
42. Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, et al. (2008) Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 380 (2): 412-420.
43. Prabakaran M, He F, Meng T, Madhan S, Yunrui T, et al. (2010) Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J Virol 84 (22): 11822-11830.
44. He F, Ho Y, Yu L, Kwang J, (2008) WSSV ie1 promoter is more efficient than CMV promoter to express H5 hemagglutinin from influenza virus in baculovirus as a chicken vaccine. BMC Microbiol 8: 238.
45. Van der Sanden S, Van der Avoort H, Lemey P, Uslu G, Koopmans M, (2010) Evolutionary trajectory of the VP1 gene of human enterovirus 71 genogroup B and C viruses, J Gen Virol 91(pt 8): 1949-1958.
46. Kung SH, Wang SF, Huang CW, Hsu CC, Liu HF, et al. (2007) Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998-2005, Clin Microbiol Infect 13 (8): 782-787.
47. Ong KC, Devi S, Cardosa MJ, Wong KT, (2010) Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 84 (1): 661-665.
48. Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, et al. (2007) Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 27 (24): 3153-3158.
49. Chen CW, Lee YP, Wang YF, Yu CK, (2011) Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 29 (15): 2772-2776.
50. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10 (11): 778-790.
51. Wu TC, Wang YF, Lee YP, Wang JR, Liu CC, et al. (2007) Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 81 (19): 10310-10315.
52. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855-1862.
53. Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, et al. (2007) An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81 (17): 9386-9395.
54. WHO Bulletin of the World Health Organization (2004) 82: 1-2: 53-58.